A user-friendly approach to drug delivery device development

Cutting-edge design that puts the patient first is at the heart of a new drug delivery device for multiple sclerosis (MS) sufferers. Product design and development firm Cambridge Consultants has worked with leading pharmaceutical company Novartis and medical device manufacturer Owen Mumford – plus hundreds of MS patients – to come up with the ExtaviPro® 30G auto-injector.

From its attractive visual design and ergonomic shape to its easy-to-read adjustable needle depth control, the ExtaviPro 30G has been designed with the needs of the patient in mind. More than 500 MS patients and healthcare professionals in the US, the UK and mainland Europe were involved in the development process to ensure the device was underpinned by a deep understanding of the users.

An estimated 2.5 million people worldwide have MS – a disease affecting the central nervous system. Symptoms can include vision problems, tingling and tremors, dizziness, balance problems, restricted mobility, fatigue and cognitive issues. The ExtaviPro 30G is aimed at people who suffer from relapsing forms of MS – such as clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) – who make up the majority of MS patients. They have periods when symptoms flare up aggressively, known as relapses, followed by periods of recovery – or remission. They often have to self-inject prescription medication at home to help reduce the impact and frequency of relapses.

“Our aim was to make the ExtaviPro 30G auto-injector very simple and intuitive to use, and enable one-handed injection,” said Andy Pidgeon, head of the industrial design and human factors group at Cambridge Consultants. “Its ergonomic shape leads patients to instinctively hold it correctly – which is vital for those who suffer from tremors, as having a firm grip is key to self-injecting safely.

“Another key factor was the feedback we received during our extensive user research. Patients wanted a soft, non-threatening design, for example – so we’ve made it very user friendly. And it’s led to the creation of a drug delivery device that doesn’t look like a badge of infirmity.”

As well as the look and feel of the auto-injector, Cambridge Consultants also developed the accompanying instruction leaflets – ensuring they were clear for MS sufferers with cognitive problems – as well as the travel bag for carrying the device and supplies for injections. To ensure the design truly reflected the needs and desires of patients, even the bag went through several rounds of user studies to ensure it best suited individual lifestyles.

The ExtaviPro 30G auto-injector has been launched in Europe – initially in Germany.

Notes to editors

Cambridge Consultants (剑桥顾问公司)开发突破性产品,产生和授权知识产权,并为全球的客户提供商业资讯,解决与技术相关的关键问题。60多年来,公司一直致力于帮助客户转化商业机会,包括推出市场领先的产品,进入新市场,引入新技术扩大现有市场。公司拥有超过900名员工,包括工程师、科学家、数学家和设计师,遍布于英国剑桥、美国波士顿、东京和新加坡办事处,为医疗和生命科学、工业和能源、消费和零售以及通讯和基础设施等多个行业提供解决方案。欲了解更多信息,请访问: www.cambridgeconsultants.com

Cambridge Consultants是 Capgemini Invent (凯捷集团的创新、咨询和转型品牌)的子公司。Capgemini Invent帮助管理者设想和构建他们组织的未来。公司在全球设有30多个办事处和25个创意工作室,是一支拥有7000多名员工的强大团队,将战略、技术、数据科学和创意设计与深厚的行业专业知识和洞察力相结合,开发新的数字解决方案和未来的商业模式。

凯捷集团是通过技术来为客户改造和管理业务的全球领导者,而Capgemini Invent是凯捷集团不可或缺的一部分。集团的宗旨是通过技术释放人类的潜能,实现包容性和可持续的未来。它是一个及负社会责任的多元化组织,在近50个国家拥有27万名团队成员。凭借其50年的悠久历史和深厚的行业专业知识,凯捷集团受到客户的信赖,在快速发展和充满创新的云、数据、人工智能、连接、软件、数字工程和平台技术的推动下,能够满足客户从战略、设计到运营的所有业务需求。集团2020年的全球营收为160亿欧元。

获得你想要的未来 | www.capgemini.com


pr-pr14-007_image1ex_v0.9.jpg, 7.3MB
pr-pr14-007_image2_v0.9.jpg, 0.7MB
pr-pr14-007_image3ex_v0.9.jpg, 5.6MB
pr-pr14-007_image4ex_v0.9.jpg, 6MB


WE Communications